Chronic graft-versus-host disease. Part II: Disease activity grading and therapeutic management.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 36572064.
- Also identified by DOI 10.1016/j.jaad.2022.12.023 and PMC identifier 10287839.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Chronic graft-versus-host disease (cGVHD) is a major complication of allogeneic hematopoietic cell transplantation and a leading cause of long-term morbidity, nonrelapse mortality, and impaired health-related quality of life. The skin is commonly affected and presents heterogeneously, making the role of dermatologists critical in both diagnosis and treatment. In addition, new clinical classification and grading schemes inform treatment algorithms, which now include 3 Federal Drug Administration-approved therapies, and evolving transplant techniques are changing disease epidemiology. Part I reviews the epidemiology, pathogenesis, clinical manifestations, and diagnosis of cGVHD. Part II discusses disease grading and therapeutic management.
Medical subject headings
- Bronchiolitis Obliterans Syndrome
- Graft vs Host Disease
- Hematopoietic Stem Cell Transplantation